Interstitial Lung Disease
An Introduction to Interstitial Lung Disease
Ongoing translational research is unearthing targetable mechanisms of disease
progression shared across the spectrum of interstitial lung diseases (ILDs). Recent approvals of antifibrotic therapies slowing loss of lung function have advanced treatment and care options for patients living with progressive ILD. Immunomodulatory agents inhibiting immune-mediated pathways (including interleukin (IL)-6-driven inflammation and adaptive immune cell responses) are currently undergoing
evaluation for disease modifying properties to preserve lung function in ILD with underlying autoimmune disease.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Interstitial Lung Disease Content
What progress is being made in the clinical management of non-IPF ILDs?
Watch a panel of world-leading ILD experts discuss current challenges in the clinical management of ILDs other than IPF (non-IPF ILDs). Prof. Toby Maher chairs a discussion with Prof. Martin Kolb and Prof. Michael Kreuter exploring challenges surrounding the diagnosis and treatment of non-IPF ILDs, and appraise how recent clinical trial data is shifting existing treatment paradigms and approaches to clinical management to improve outcomes for patients living with non-IPF ILDs.
- Discuss how to improve the accurate and early diagnosis of non-IPF ILDs
- Evaluate the current unmet needs in the management of patients with non-IPF ILDs
- Analyse the emerging treatment options for non-IPF ILDs
Nintedanib—A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease
US Respiratory and Pulmonary Diseases. 2020;5(1):28-32 DOI: https://doi.org/10.17925/USPRD.2020.5.1.28
Systemic sclerosis (SSc) is an autoimmune disorder characterized by inflammation and fibrosis of the skin and other organs. It has a range of clinical manifestations, and the typical internal organs involved include the lungs, kidneys, heart, and gastrointestinal tract. Though it is an uncommon condition, the mortality rate of this disease is higher than any […]
Lauren Troy, ERS 2019 – Transbronchial Lung Cryobiopsy for Interstitial Lung Disease Diagnosis
We met with Lauren Troy, from Royal Prince Alfred Hospital, Sydney, Australia at ERS 2019 in Madrid to discuss result of the COLDICE study into transbronchial lung cryobiopsy for interstitial lung disease diagnosis. Questions 1. In what clinical situation is a lung biopsy required to confirm a diagnosis of interstitial lung disease? (0:05) 2. What […]
Toby Maher, ERS 2019 – Pirfenidone in Patients with Progressive Fibrosing Unclassifiable ILD
Toby Maher, Royal Brompton Hospital, London, met with us at ERS 2019 in Madrid to discuss the results of a Phase II trial of pirfenidone in patients with progressive fibrosing unclassifiable ILD (uILD). Questions 1. What is the definition of unclassifiable interstitial lung disease (uILD) and what proportion of ILD patients are considered unclassifiable? (0:05) […]
Mary E Strek, CHEST 2018 – Autoimmune lung diseases
Mary E Strek (University of Chicago, Chicago, IL, US) brings us up to speed on important aspects of autoimmune lung diseases. Questions 1. How prevalent are autoimmune lung diseases? (0:10) 2. What are the major autoimmune causes of interstitial lung diseases? (0:36) 3. What are the major challenges in the diagnosis and treatment of autoimmune […]
Jonathan H Chung, CHEST 2018 – Radiology of interstitial lung diseases
Jonathan H Chung (University of Chicago, Chicago, IL, US) shares his expert insights on radiology imaging of interstitial lung diseases. Questions 1. What are the most radiologic characteristics of the different types of interstitial lung disease (ILD)? (0:10) 2. What further investigations are required to confirm the radiologic diagnosis of ILD? (1:13) 3. How do […]
Simon Walsh, ERS 2018 – A new algorithm for classifying fibrotic lung disease
Simon Walsh (King’s College NHS Foundation Trust, King’s College London, London, UK) discusses the background and findings of his late-breaking presentation entitled: A Deep Learning Algorithm for Classifying Fibrotic Lung Disease on High Resolution Computed Tomography. Questions 1. What are the current standard techniques for diagnosing and classifying fibrotic lung disease? (0:12) 2. What are […]
The Bleeding Pneumonia — A Review of Diffuse Alveolar Hemorrhage
US Respiratory & Pulmonary Diseases. 2018;3(1):33–6 DOI: https://doi.org/10.17925/USRPD.2018.3.1.33
Highlights Diffuse alveolar hemorrhage (DAH), though rare, can be fatal and requires a high index of suspicion as frank hemoptysis may not be a presenting symptom. Multilobar pneumonia can simulate DAH both clinically and radiographically. Diagnosis relies on a strong clinical suspicion, laboratory studies, imaging, and pathology. Overall incidence of DAH is difficult to […]
Yohannes Ghebre, ATS 2018 – Proton pump inhibitors in idiopathic pulmonary fibrosis
Yohannes Ghebre (Baylor College of Medicine, Houston, TX, US) discusses the rationale and clinical evidence to date for using proton pump inhibitors (PPIs) to treat idiopathic pulmonary fibrosis (IPF). Questions 1. What are the limitations of the currently approved drugs, pirfenidone and nintedanib, in idiopathic pulmonary fibrosis (IPF)? (0:11) 2. What is the rationale for […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!